8GPU image
Entry Detail
PDB ID:
8GPU
Title:
YFV_E_YD6Fab_prefusion
Biological Source:
PDB Version:
Deposition Date:
2022-08-27
Release Date:
2022-11-02
Method Details:
Experimental Method:
Resolution:
2.79 Å
R-Value Free:
0.27
R-Value Work:
0.24
R-Value Observed:
0.24
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Envelope protein
Chain IDs:A, D (auth: E), G (auth: B), J (auth: I), M, P
Chain Length:398
Number of Molecules:6
Biological Source:Yellow fever virus
Polymer Type:polypeptide(L)
Description:YD6Fab_H
Chain IDs:B (auth: H), E (auth: F), H (auth: C), K (auth: J), N, Q
Chain Length:217
Number of Molecules:6
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:YD6Fab_L
Chain IDs:C (auth: L), F (auth: G), I (auth: D), L (auth: K), O, R
Chain Length:217
Number of Molecules:6
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus.
Innovation (N Y) 3 100323 100323 (2022)
PMID: 36199277 DOI: 10.1016/j.xinn.2022.100323

Abstact

The yellow fever virus (YFV) is a life-threatening human pathogen. Owing to the lack of available therapeutics, non-vaccinated individuals are at risk. Here, we isolated eight human monoclonal antibodies that neutralize YFV infection. Five recognized overlapping epitopes and exhibited potent neutralizing activity. Two (YD6 and YD73) were ultra-potent and conferred complete protection against the lethal challenge of YFV as both prophylactics and therapeutics in a mouse model. Crystal structures revealed that YD6 engaged the YFV envelope protein in both pre- and post-fusion states, suggesting viral inhibition by a "double-lock" mechanism. The recognition determinants for YD6 and YD73 are clustered at the premembrane (prM)-binding site. Notably, antibodies targeting this site were present in minute traces in YFV-infected individuals but contributed significantly to neutralization, suggesting a vulnerable supersite of YFV. We provide two promising candidates for immunotherapy against YFV, and the supersite represents an ideal target for epitope-based vaccine design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures